TAK-137 is a novel AMPA receptor potentiator with little agonistic effect, producing antidepressant-like effect without causing psychotomimetic effects.
OV-potentiator-28 is a potentiator of cancer virotherapy. OV-potentiator-28 significantly enhances virus replication-associated luciferase expression, specifically in tumors.
Cinepazide is a vasodilator used for the treatment of cardiovascular, cerebrovascular, and peripheral vascular diseases. Cinepazide acts as a potentiator of adenosine A2 receptors.
5-MPEP is a neutral allosteric site ligand of the metabotropic glutamate receptor subtype 5 (mGlu5), blocking the effects of both the allosteric antagonist MPEP and potentiator CDPPB.
SPR741, formerly NAB741 (12), is a cationic peptide derived from polymyxin B and is one such potentiator molecule that is under development for the treatment of serious Gram-negative bacterial infections.
Dirocaftor (PTI-808) is a CFTR potentiator that augments CFTR protein function via the activation of chloride channels. Dirocaftor holds potential utility for research pertaining to cystic fibrosis (CF).
KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.
CP-628006 is a small molecule CFTR potentiator that effectively restores ATP-dependent channel gating to G551D-CFTR, the mutant form found in cystic fibrosis.
LY503430 is a AMPA receptor potentiator with oral activity. LY503430 has both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP.